Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  American Society of Nephrology. Clinical Journal

• Publication date

  2018-03-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.2215/CJN.05280517PMID 29339356PMCID PMC5967667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discrimination slope and integrated discrimination improvement – properties, relationships and impact of calibration

  2017cited by this paper
• Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin

  2016cited by this paper
• Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

  2016cited by this paper
• Novel Tubular Biomarkers Predict Renal Progression in Type 2 Diabetes Mellitus: A Prospective Cohort Study

  2016cited by this paper
• Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.

  2016cited by this paper
• Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study.

  2015cited by this paper
• Cross-Disciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium.

  2015cited by this paper
• Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging

  2014cited by this paper
• Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus

  2014cited by this paper
• Biomarkers in nephrology: Core Curriculum 2013.

  2013cited by this paper
• Combined angiotensin inhibition for the treatment of diabetic nephropathy.

  2013cited by this paper
• Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Longitudinal progression trajectory of GFR among patients with CKD.

  2012cited by this paper
• Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

  2012cited by this paper
• Renal Function Trajectory Is More Important than Chronic Kidney Disease Stage for Managing Patients with Chronic Kidney Disease

  2012cited by this paper
• Urinary biomarkers and renal recovery in critically ill patients with renal support.

  2011cited by this paper
• New markers of acute kidney injury: giant leaps and baby steps.

  2011cited by this paper
• [New markers of acute kidney injury].

  2010cited by this paper
• Review: Serum and urine biomarkers of kidney disease: A pathophysiological perspective

  2010cited by this paper
• Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.

  2009cited by this paper
• A new equation to estimate glomerular filtration rate.

  2009cited by this paper
• Neutrophil Gelatinase-Associated Lipocalin as an Early Biomarker of Nephropathy in Diabetic Patients

  2009cited by this paper
• Early detection of acute kidney injury: Emerging new biomarkers (Review Article)

  2008cited by this paper
• Illness trajectories: an important concept in the management of kidney failure.

  2008cited by this paper
• Projecting the number of patients with end-stage renal disease in the United States to the year 2015.

  2005cited by this paper
• Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery

  2005cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Model of Complications of NIDDM: I. Model construction and assumptions

  1997cited by this paper
• The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

  1994cited by this paper
• The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

  1994cited by this paper
• Modification of diet in renal disease.

  1992influential reference

• Plasma and Urinary KIM-1 in Chronic Kidney Disease: Prognostic Value, Associations with Albuminuria, and Implications for Kidney Failure and Mortality.

  2025cites this paper
• Emerging microchemical sensors for real-time point-of-care detection of chronic kidney disease biomarkers

  2025cites this paper
• Long-Term Cardiorenal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Real-World Single-Center Experience

  2025influential citation
• Disease Progression Modeling of Estimated Glomerular Filtration Rate (eGFR): A Pharmacometrics Approach

  2025influential citation
• The relationship between trajectories of renal oxygen saturation and acute kidney injury: a prospective cohort study with a secondary analysis

  2024cites this paper
• Ae index is an independent predictor of kidney stone recurrence in overweight and obese patients

  2023cites this paper
• Predictive Analytics with a Transdisciplinary Framework in Promoting Patient-Centric Care of Polychronic Conditions: Trends, Challenges, and Solutions

  2023cites this paper
• Effect of Glomerular Filtration Rate by Different Equations on Prediction Models for End-Stage Renal Disease in Diabetes

  2022cites this paper
• Renal function decline and heart failure hospitalisation in patients with type 2 diabetes: dynamic predictions from the prospective SURDIAGENE cohort.

  2022cites this paper
• Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

  2022influential citation
• Development and validation of a risk prediction model for chronic kidney disease among individuals with type 2 diabetes

  2022cites this paper
• Prognostic models of diabetic microvascular complications: a systematic review and meta-analysis

  2021influential citation
• Bisphenol A Modulates Autophagy and Exacerbates Chronic Kidney Damage in Mice

  2021cites this paper
• PRKAA2 variation and the clinical characteristics of patients newly diagnosed with type 2 diabetes mellitus in Yogyakarta, Indonesia

  2021cites this paper
• Comparison of the renal effects of bisphenol A in mice with and without experimental diabetes. Role of sexual dimorphism.

  2021cites this paper
• Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial

  2021cites this paper
• SGLT2i agonist and GLP-1 receptor COMBination therapy in type 2 diabetes: Protocol for a KIDney endpoints real world study-[COMBi-KID Study] (Preprint)

  2021cites this paper
• Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all‐cause mortality in individuals with type 2 diabetes in the ADVANCE trial

  2020cites this paper
• Urine S-Adenosylmethionine are Related to Degree of Renal Insufficiency in Patients with Chronic Kidney Disease.

  2020cites this paper
• Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD.

  2020cites this paper
• Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence

  2020cites this paper
• Serially assessed bisphenol A and phthalate exposure and association with kidney function in children with chronic kidney disease in the US and Canada: A longitudinal cohort study

  2020cites this paper
• Methylation pattern of urinary DNA as a marker of kidney function decline in diabetes

  2020cites this paper
• Estimated GFR Decline and Tubular Injury Biomarkers With Intensive Blood Pressure Control.

  2019cites this paper
• Variations in glucose/C-peptide ratio in patients with type 2 diabetes associated with renal function.

  2019cites this paper
• Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

  2019cites this paper
• Series: Cardiovascular outcome trials for diabetes drugs Alogliptin and EXAMINE

  2019cites this paper
• Comparison and development of machine learning tools in the prediction of chronic kidney disease progression

  2019cites this paper
• STORIA NATURALE DELLA MALATTIA RENALE NEL DIABETE E TRATTAMENTO DELL’IPERGLICEMIA NEI PAZIENTI CON DIABETE DI TIPO 2 E RIDOTTA FUNZIONE RENALE

  2019cites this paper
• Frecuencia y características de la Nefropatía Diabética en consulta externa del Hospital Regional Vicente Corral Moscoso, Cuenca-Ecuador, 2014–2016.

  2018cites this paper
• Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes

  2018cites this paper
• Diagnostic accuracy of neutrophil gelatinase-associated lipocalin Diagnostic accuracy of neutrophil gelatinase-associated lipocalin as a predictor of chronic kidney disease as a predictor of chronic kidney disease

  year unknowncites this paper